Searched over 200M research papers for "angina treatment"
10 papers analyzed
These studies suggest that angina treatment involves a combination of pharmacological therapies, novel drugs, acupuncture, and advanced revascularization strategies, with individualized approaches being necessary for optimal management.
20 papers analyzed
Angina pectoris, a symptom of myocardial ischemia, has traditionally been managed with beta-blockers, calcium channel blockers, and nitrates. Beta-blockers are often the first line of treatment due to their efficacy in reducing cardiac events and improving survival rates post-myocardial infarction. Calcium channel blockers serve as a second-line treatment when beta-blockers are contraindicated or cause adverse effects, offering relief by reducing heart rate and causing vasodilation. Nitrates, both short-acting and long-acting, are used to alleviate acute angina attacks and improve exercise tolerance.
Recent advancements have introduced new classes of anti-anginal drugs that offer additional options for patients who do not respond adequately to traditional therapies. Ranolazine, trimetazidine, nicorandil, ivabradine, and fasudil are among the novel agents that have shown promise in clinical trials . These drugs work through various mechanisms, such as improving myocardial metabolic efficiency and reducing heart rate, thereby complementing traditional therapies and providing more comprehensive management of angina .
Acupuncture has emerged as a potential adjunctive therapy for chronic stable angina. Clinical trials have demonstrated that acupuncture, particularly when applied to disease-affected meridians, significantly reduces the frequency of angina attacks compared to sham acupuncture or no acupuncture. Meta-analyses further support the efficacy of acupuncture, showing improvements in anginal symptoms and electrocardiographic results when used alongside conventional medical treatments.
Refractory angina, characterized by persistent symptoms despite optimal medical therapy and revascularization, remains a significant challenge. Conventional pharmacological approaches include the use of second- and third-line agents, while advanced revascularization techniques such as chronic total occlusion PCI and transmyocardial laser revascularization are also explored . Additionally, novel therapies like angiogenetic and stem cell treatments are under investigation for their potential to reduce ischemia and alleviate pain .
A systematic review has highlighted the underrepresentation of women in clinical trials for anti-anginal medications, leading to a lack of gender-specific data. This gap underscores the need for more inclusive research to ensure that treatment recommendations are equally effective for both men and women.
The treatment landscape for angina pectoris is evolving with the introduction of novel pharmacological agents and alternative therapies like acupuncture. While traditional treatments remain foundational, emerging drugs and advanced revascularization techniques offer new hope for patients with refractory angina. Addressing gender disparities in clinical research is crucial for developing comprehensive and effective treatment strategies for all patients.
Most relevant research papers on this topic